Explore

Rapid ReadRapid Read
Editas Medicine Prepares for First Human Trial of CRISPR Cholesterol Therapy EDIT-401

Editas Medicine Prepares for First Human Trial of CRISPR Cholesterol Therapy EDIT-401

Editas Medicine is advancing towards a first-in-human study for EDIT-401, an in vivo CRISPR-edited medicine designed to reduce LDL cholesterol in patients with heterozygous familial hypercholesterolemia. According to CEO Gilmore O’Neill, the company is focused on in vivo CRISPR-edited medicines that offer differentiated efficacy and utilize gene-editing capabilities. EDIT-401 aims to increase the production of LDL receptors in liver cells, thereby enhancing the removal of LDL cholesterol from the bloodstream. Preclinical findings in non-human primates showed a mean reduction of 90% in LDL cholesterol, lipoprotein(a), and apolipoprotein B. The treatment is designed as a single intravenous infusion. Editas Medicine has submitted documentation to human research ethics committees in Australia and plans to dose the first patients this year. The Phase 1 trial will involve serial dose-escalation cohorts and an expansion into a broader patient population. The company anticipates sharing safety data in the first qu...
TrendlineTrendline
Ridge Biotechnologies Secures Additional Investment to Advance AI-Designed Bioconjugate Therapeutics

Ridge Biotechnologies Secures Additional Investment to Advance AI-Designed Bioconjugate Therapeutics

Ridge Biotechnologies Secures Additional Investment to Advance AI-Designed Bioconjugate Therapeutics
Rapid ReadRapid Read
Gene Therapy Extends Lifespan and Reduces Symptoms in Feline Sandhoff Disease Model

Gene Therapy Extends Lifespan and Reduces Symptoms in Feline Sandhoff Disease Model

A new study has demonstrated that intravenous gene therapy can extend the lifespan and reduce symptoms in a cat model of Sandhoff disease. Sandhoff disease, along with Tay-Sachs disease, is a fatal neurodegenerative lysosomal storage disorder characterized by the toxic accumulation of fat in nerve cells of the brain and spinal cord due to the absence of β-hexosaminidase (Hex) enzymes. Currently, there are no available therapies for these conditions, which typically lead to the death of affected children around four years of age. The gene therapy tested in this study utilized an adeno-associated virus (AAV) vector expressing the two Hex enzymes. Previous clinical trials for Sandhoff disease involved injecting AAV gene therapy directly into the brain or cerebrospinal fluid. However, this new research, published in Science Translational Medicine, marks the first time intravenous AAV gene therapy has been evaluated for this condition. The study investigated the delivery of a bicistronic AAV vector to presympto...
TrendlineTrendline
Cellipont Bioservices and Xiogenix Publish White Paper on Automated Fill-Finish for Cell Therapy Manufacturing

Cellipont Bioservices and Xiogenix Publish White Paper on Automated Fill-Finish for Cell Therapy Manufacturing

Cellipont Bioservices and Xiogenix Publish White Paper on Automated Fill-Finish for Cell Therapy Manufacturing
Rapid ReadRapid Read
Nanorobotics Market Projected to Reach $31.44 Billion by 2034 Amidst Growth in Precision Medicine

Nanorobotics Market Projected to Reach $31.44 Billion by 2034 Amidst Growth in Precision Medicine

The global nanorobotics market is projected to reach USD 31.44 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 14.9% during the forecast period of 2026-2034, according to a new report by Polaris Market Research. The market, valued at USD 9.01 billion in 2025, is experiencing steady growth driven by the increasing adoption of precision medicine, rising investment in nanomedicine research, and continuous advancements in nano-engineering. Key applications include targeted drug delivery systems, regenerative medicine platforms, and minimally invasive treatment technologies. North America held the largest revenue share in 2025, accounting for approximately 40.9%, primarily due to strong funding for nanomedicine research and advanced healthcare infrastructure. Microbivore nanorobots led the type segment in 2025, while cell-repair nanorobots are expected to see the fastest expansion. Drug delivery remains the largest application segment, with regenerative medicine applications forecasted for r...
TrendlineTrendline
Ainnocence Inc. Unveils AINN-P1 Protein Model Outperforming Larger AI in Drug Discovery

Ainnocence Inc. Unveils AINN-P1 Protein Model Outperforming Larger AI in Drug Discovery

Ainnocence Inc. Unveils AINN-P1 Protein Model Outperforming Larger AI in Drug Discovery
TrendlineTrendline
Rakuten Medical Appoints Christophe Weber and Ken Takeshita to Board, Hassan Danesi as CMO to Accelerate U.S. Growth and Oncology Innovation

Rakuten Medical Appoints Christophe Weber and Ken Takeshita to Board, Hassan Danesi as CMO to Accelerate U.S. Growth and Oncology Innovation

Rakuten Medical Appoints Christophe Weber and Ken Takeshita to Board, Hassan Danesi as CMO to Accelerate U.S. Growth and Oncology Innovation
TrendlineTrendline
Countable Labs Expands Global Reach with New Japanese Distribution Partnership

Countable Labs Expands Global Reach with New Japanese Distribution Partnership

Countable Labs Expands Global Reach with New Japanese Distribution Partnership
TrendlineTrendline
U.S. Representative Kevin Mullin Praises Gilead's New Research Center in Foster City

U.S. Representative Kevin Mullin Praises Gilead's New Research Center in Foster City

U.S. Representative Kevin Mullin Praises Gilead's New Research Center in Foster City
Rapid ReadRapid Read
Nanochon Initiates First-in-Human Clinical Study for Chondrograft™ 3D-Printed Knee Implant

Nanochon Initiates First-in-Human Clinical Study for Chondrograft™ 3D-Printed Knee Implant

Nanochon, a medical device company, has successfully treated the first patient in its First-in-Human (FIH) clinical study for Chondrograft™, a novel 3D-printed implant designed to treat articular cartilage defects in the knee. The procedure was performed by Dr. Juan Osorio and Dr. Emilio Tufiño at The Panama Clinic in Panamá. This prospective study aims to evaluate the safety and performance of Chondrograft™ in patients aged 22 to 60 who have not responded to conservative treatments and have one or two femoral condyle and/or trochlear cartilage lesions. The Chondrograft™ implant is intended to offer immediate mechanical support and a minimally invasive, bone-sparing solution for patients with cartilage damage who are not yet candidates for joint replacement surgery. Nanochon's co-founder and CEO, Ben Holmes, highlighted the rapid enrollment of the first patient as an indicator of the significant unmet clinical need in cartilage repair.
Rapid ReadRapid Read
Aptar Pharma and Aceso Therapeutics Collaborate to Advance Inhaled Cystic Fibrosis Therapy

Aptar Pharma and Aceso Therapeutics Collaborate to Advance Inhaled Cystic Fibrosis Therapy

Aptar Pharma, a leader in drug delivery technologies, has announced a collaboration with Aceso Therapeutics, a biotech company focused on novel cystic fibrosis (CF) therapies. This partnership aims to advance the development of ACT-101, an antisense oligonucleotide (ASO) candidate designed to target the underlying disease mechanisms of CF. Aptar Pharma's specialist inhalation development services business, Nanopharm, will lead the formulation development and device assessment activities for ACT-101. This initiative is part of Aptar Pharma's broader biologics compatibility program, which evaluates how complex biologic molecules interact with their pulmonary and nasal delivery platforms. Cystic fibrosis is a rare, inherited disease that severely damages the lungs, digestive system, and other organs, affecting approximately 100,000 people worldwide. The collaboration seeks to accelerate ACT-101's development towards clinical evaluation, exploring its potential through direct delivery to the lung.
Rapid ReadRapid Read
Deaths in Chinese Gene-Editing Trials Raise Global Concerns Over Oversight and Ethics

Deaths in Chinese Gene-Editing Trials Raise Global Concerns Over Oversight and Ethics

The deaths of two children in separate gene-editing trials in China have sparked significant concerns among researchers, ethicists, and legal scholars regarding the oversight and ethical standards within the country's biomedical industry. One death involved a trial conducted by HuidaGene Therapeutics for Duchenne muscular dystrophy, where a boy died from acute respiratory distress syndrome. The other case involved a young girl who died after receiving an experimental gene therapy for Snijders Blok–Campeau syndrome, a trial pioneered by neuroscientist Zilong Qiu and clinician Yongguo Yu. Investigations by Science and Retraction Watch revealed potential ethical breaches, including direct communication between the researcher and the family, and the administration of the therapy despite evidence of harm in animal toxicology studies. These incidents highlight the risks associated with gene therapies and the critical need for stringent regulatory oversight.